CommercialDocumentationHigh impact
08.01.62e, Nivolumab (Opdivo®), Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 24, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.62e has been updated effective March 24, 2025, with changes to medical necessity criteria, medical coding, and general guidelines for Nivolumab (Opdivo®) and Nivolumab and Hyaluronidase-nvhy (Opdivo Qvantig™). The billing team must review the full policy text to identify specific coding and coverage requirement changes for these immunotherapy drugs.
Action Required
By March 24, 2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-62e to identify specific HCPCS drug codes, medical necessity documentation requirements, and any prior authorization changes. Update billing system rules, encounter forms, and provider education materials accordingly. Document all changes in internal policy tracker. Contact the payer directly if specific codes are not clearly listed in the policy document. Failure to implement required changes may result in claim denials for Opdivo/Opdivo Qvantig administrations.